Version date: 4/4/2022 (v16)

# Pfizer-BioNTech COVID-19 Vaccine Consent Form Facility: St. Mary's Medical Center – SFO Medical Clinic

Section 1: Personal Information (please print)

-	tion 1. Personal information (please p	<u> </u>			
	NAME (Last)	(First)	(M.I.)	Address	
	DATE OF BIRTH: month d	layyear	·	City	State
	PHONE NUMBER	SEX ASSIGNED AT BIRTH	M / F	7in Codo	Country
	EMAIL ADDRESS			Zip Code	Country

Secti	on 2: Screening for Vaccine Eligibility	YES	NO	N/A
1.	Have you had a severe allergic reaction after receiving a previous dose of an mRNA (Pfizer-BioNTech or			
	Moderna) COVID-19 vaccine?			
2.	Have you had an intermediate or severe allergic reaction to any ingredient in the Pfizer-BioNTech COVID- 19 vaccine or to polysorbate?			
	Components of the Pfizer-BioNTech COVID-19 Vaccine: nucleoside-modified messenger RNA (modRNA)			
	encoding the viral spike (S) glycoprotein of SARS-CoV-2, sodium chloride, lipids, polyethylene glycol,			
	potassium chloride, monobasic potassium phosphate, dibasic sodium phosphate dihydrate, and sucrose			
3.	Are you below the minimum age requirement (5 years) for receiving the Pfizer-BioNTech COVID-19 vaccine?			
4.	For primary series vaccine doses (initial 2 doses, 3 doses for immunocompromised people), have you			
	received a previous COVID-19 vaccine made by a different manufacturer? Your initial doses should be			
	made by the same manufacturer. For booster doses, please select N/A.			
5.	Are you moderately or severely immunocompromised (see details on page 2) and 5 years of age or older?			
	If yes, you are eligible for a third vaccine dose, to be given at least 28 days after your second dose. If you			
	are immunocompromised and 12 years of age or older, you may also receive a fourth (booster) dose 3			
	months after your third vaccine dose.			
6.	If you have completed a primary vaccine series with the Pfizer-BioNTech COVID-19 vaccine or the			
	Moderna COVID-19 vaccine, do the below criteria apply to you?			
•	Pfizer-BioNTech COVID-19 vaccine:			
•	12 years of age or older and at least 5 months has elapsed since your second dose			
•	50 years of age or older and at least 4 months has elapsed since your first booster shot			
•	12 years of age or older, moderately or severely immunocompromised, and at least 4 months has elapsed			
	since your first booster shot			
•	Moderna COVID-19 vaccine:			
•	18 years of age or older and at least 5 months has elapsed since your second dose			
•	50 years of age or older and at least 4 months has elapsed since your first booster shot			
•	18 years of age or older, moderately or severely immunocompromised, and at least 4 months has elapsed since your first booster shot			
If yes	, the Centers for Disease Control and Prevention (CDC) recommends a COVID-19 vaccine booster shot for you.			
Any o	of the currently available COVID-19 vaccines may be used for your booster dose (this consent form is for the			
Pfize	r-BioNTech COVID-19 vaccine).			
7.	If you have completed the single primary dose of the Janssen COVID-19 vaccine, do the below criteria			
	apply to you?			
•	18 years of age or older			
•	At least 2 months has elapsed since your dose	1		
-	, the CDC recommends a COVID-19 vaccine booster shot for you. Any of the currently available COVID-19			
vacci	nes may be used for your booster dose (this consent form is for the Pfizer-BioNTech COVID-19 vaccine).			
8.	Have you received both a single primary dose and booster dose of the Janssen COVID-19 vaccine? If yes,			
	you may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after your			
	Janssen COVID-19 booster.			

For the first 4 questions, if 'no' or 'N/A' answers, progress to the next section. For 'yes' answers, please seek guidance.

### **Section 3: Consent for Vaccination**

- I have been offered and have read or had explained to me the COVID-19 Vaccine Screening Questions and Guidance.
- I also have been offered and have read or had explained to me the Fact Sheet for Patients and Parents/Caregivers for the Pfizer-BioNTech COVID-19 Vaccine that I am receiving today.

Version date: 4/4/2022 (v16)

- I understand the risks and benefits of receiving the Pfizer-BioNTech COVID-19 Vaccine.
- I understand the Pfizer-BioNTech COVID-19 Vaccine is FDA approved for people 16 years of age and older. For people 5 to 15 years of age, the third dose for certain immunocompromised people, and the booster dose(s) for certain people 12 years of age and older, the Pfizer-BioNTech COVID-19 Vaccine is available under emergency use authorization (EUA) and has not been fully reviewed and approved by the FDA.
- I understand the potential risks, including serious allergic reactions (anaphylaxis). Other reported adverse reactions include injection site pain, swelling, redness, fatigue, headache, muscle pain, chills, joint pain, fever, nausea, and swollen lymph nodes.
- I understand there may be other potential ways to prevent COVID-19.
- I was given the chance to ask questions and all questions were answered.
- I agree to receive the Pfizer-BioNTech COVID-19 Vaccine.
- I GIVE CONSENT to The Facility and its staff to vaccinate me or the person named above with the Pfizer-BioNTech COVID-19 Vaccine (the COVID Vaccine). (If you choose this option but do not sign below, then you or the person named above for whom you are giving consent will not be vaccinated).

Signature of Recipient/Healthcare Proxy	_ Date: month	_day	_year
If signing for someone other than yourself - Printed Name:	Relationship:		

#### **Section 4: Definitions**

#### Moderately or severely immunocompromised

Your provider is best able to assess your degree of immunocompromise and optimal timing of vaccination. Moderate or severe immune compromise may be caused by immunosuppressive or immunomodulatory therapies (for example, active cancer treatment, CART-T-cell therapy, high-dose steroids) or medical conditions that affect the immune system (for example, solid-organ transplant, stem cell transplant within last 2 years, moderate or severe primary immunodeficiency, advanced or untreated HIV infection).

#### **Section 5: Notice of Privacy Practices**

- I have been offered The Facility's Notice of Privacy Practices.
- By signing below, I acknowledge receipt of the Notice of Privacy Practices.

Signature of Recipient/Healthcare Proxy	Date: monthday	_year	
---	----------------	-------	--

#### Section 6: Consent to Bill/Assignment of Benefits

- I will not be personally responsible for any cost or fee associated with the COVID Vaccine.
- If I am a beneficiary under any insurance or health plan or government-sponsored program (Plan/Program), I understand that the Plan/Program may be billed for the administration of the COVID Vaccine.
- I assign to The Facility any benefits under my Plan/Program for the administration of the COVID Vaccine.
- I authorize The Facility to directly bill my Plan/Program for the administration of the COVID Vaccine.
- I instruct my Plan/Program to directly pay The Facility any benefits to which I am entitled for the administration of the COVID Vaccine.
- I authorize The Facility to keep any payment received from my Plan/Program for the administration of the COVID Vaccine.

	_	_		
Signature of Recipient/Healthcare Proxy	Date: month	dav	vear	
Signature of Recipient/ Healtheare Froxy	. Date: month_	uuy	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

#### Section 7: Vaccination Record

#### FOR ADMINISTRATIVE USE ONLY

Vaccine Manufacturer	Date Dose Administered	Lot Number	Dose	Name of Vaccine Administrator
			☐ First Dose	
Pfizer/BioNTech	/ /		Second Dose	
•			☐ Third Dose	
			☐ Booster Dose #1	
			☐ Booster Dose #2	

Injection Site: Left /	Right Deltoid	Time:	AM	/ PN

## **COVID-19 Vaccine Screening Questions and Guidance**

Pertains to Pfizer-BioNTech, Moderna, and Janssen (J&J) COVID Vaccines

Question			Answer		
Have you had a severe allergic reaction or immediate allergic reaction after receiving a previous dose of an mRNA COVID-19 vaccine (made by Pfizer-BioNTech or Moderna)?	☐ Yes	□ No	□ N/A		
Guidance: If yes, you should not receive another mRNA COVID-19 vaccine dose without talking to your provider. Please ask your provider if they think your allergic reaction is severe. An immediate allergic reaction is allergic signs, such as itching, swelling of the tongue, neck or throat, wheezing, or anaphylaxis within 4 hours of the vaccine administration. Your provider should help you decide if you should receive a second dose.  If you had a severe allergic reaction or immediate allergic reaction to an mRNA COVID-19 vaccine dose, you may be able to receive a Janssen COVID-19 vaccine					
dose (at least 28 days after mRNA dose). However, caution must be used. You should be vaccinated in a setting under the supervision of a health care provider experienced in the management of severe allergic reactions. Consider asking your provider to refer you to an allergist-immunologist.					
Have you had a severe allergic reaction or immediate allergic reaction to any ingredient in the COVID-19 vaccines?  Components of the Pfizer-BioNTech COVID-19 Vaccine: nucleoside-modified	□ Vaa				
messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2, sodium chloride, lipids, polyethylene glycol, potassium chloride, monobasic potassium phosphate, dibasic sodium phosphate dihydrate, and sucrose	☐ Yes	□N	O		
<b>Components of the Moderna COVID-19 Vaccine</b> : nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus, lipids, polyethylene glycol [PEG], tromethamine, acetic acid, sodium acetate, and sucrose.	□ Yes	□ N	0		
Components of the Janssen COVID-19 Vaccine: recombinant replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-6-cyclodextrin (HBCD), polysorbate-80, sodium chloride.  Guidance: If yes, you should not receive this vaccine.	□ Yes	□ <b>N</b>	o		
Are you in need of COVID-19 vaccination but are unable (e.g., allergy) or unwilling to	☐ Yes	□ <b>N</b>	0		
Guidance: If yes, a Janssen (J&J) COVID-19 Vaccine may be an option for you.  However, in most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for primary and booster vaccination.					
Do you have a personal history of a severe allergic reaction to any vaccine or injectable therapy (intramuscular, intravenous, or subcutaneous)? <u>Guidance</u> : If yes, you may receive a COVID-19 vaccine. You will be watched for 30 minutes after today's vaccination to see if you have any reactions.	☐ Yes	□N	0		

Question	Answer		
Do you have a personal history of a severe allergic reaction to any oral medications,	☐ Yes ☐ No		
food, or environmental factors, such as pets or latex?			
Guidance: If yes, you may receive a COVID-19 vaccine. If you have had a severe			
allergic reaction due to any cause, you will be watched for 30 minutes after			
today's vaccination to see if you have any reactions. If your allergic reaction was			
not severe, you will be watched for the usual 15-minute period.			
Are you below the minimum age requirement (for primary vaccine series)?			
Pfizer-BioNTech COVID-19 vaccine: 5 years	☐ Yes ☐ No		
Moderna COVID-19 vaccine: 18 years	☐ Yes ☐ No		
Janssen COVID-19 vaccine: 18 years	☐ Yes ☐ No		
<u>Guidance</u> : If yes, you should not receive this vaccine. To get the vaccine, you			
must meet the age requirement for the vaccine you are receiving.			
Have you received a previous COVID-19 vaccine made by a different manufacturer?	☐ Yes ☐ No		
<u>Guidance</u> : If yes (for primary vaccine series), you should receive your second			
dose made by the same vaccine manufacturer. While any of the currently			
available COVID-19 vaccines may be used for your booster dose, in most			
situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over			
the Janssen COVID-19 vaccine for booster vaccination.			
If you received the first dose of mRNA COVID-19 vaccine but you are unable to			
receive the second dose with same or different mRNA vaccine due to a			
contraindication, you may receive a single dose of the Janssen COVID-19 vaccine			
28 days after mRNA COVID-19 vaccine dose. However, caution must be used. You			
should be vaccinated in a setting under the supervision of a health care provider			
experienced in the management of severe allergic reactions. Consider asking			
your provider to refer you to an allergist-immunologist.			
Has too little time elapsed since your first COVID-19 vaccine dose?	☐ Yes ☐ No ☐ N/A		
Pfizer-BioNTech COVID-19 vaccine: 21 days	- 100 - 110 - 114		
Moderna COVID-19 vaccine: 28 days			
Janssen COVID-19 vaccine: not applicable, one dose only			
Guidance: If yes, you should wait the recommended amount of time to get your			
second dose. You may receive it 4 days earlier if needed.			
The second dose should be administered as close to the recommended interval			
as possible. An 8-week interval (between 1 <sup>st</sup> and 2 <sup>nd</sup> doses) may be optimal for			
some people ages 12 years and older, especially for males ages 12 to 39 years			
old. The standard interval between vaccine doses (3 weeks for Pfizer-BioNTech;			
4 weeks for Moderna) remains the recommended interval for the following			
people: moderately to severely immunocompromised, adults $\geq$ 65 years of age,			
and others who need rapid protection due to increased concern about			
community transmission or risk of severe disease.			
Have you been diagnosed with COVID-19 infection previously?	☐ Yes ☐ No		
Guidance: If yes, you may receive a COVID-19 vaccine. Clinical trials indicate it is			
safe.			
Do you currently have COVID-19 symptoms (including fever) OR a current diagnosis	☐ Yes ☐ No		
of COVID-19?			

Question	Answer
Guidance: If yes, wait to get the vaccine until you have recovered from your	
acute illness and your quarantine period has ended to avoid exposing healthcare	
workers (HCW) or others during your vaccination appointment. You may wait to	
get the vaccine after your infection, but waiting is not required.	
Are you moderately or severely immunocompromised?	☐ Yes ☐ No
Guidance: If yes, you may receive a third dose of either the Pfizer-BioNTech or	
Moderna COVID-19 vaccine, at least 28 days after your second dose if you are 5	
years of age or older (Pfizer-BioNtech) or 18 years of age or older (Moderna).  You may also receive a fourth (booster) dose 3 months after your third vaccine	
dose for the Pfizer-BioNTech COVID-19 vaccine (12 years of age or older) and 3	
months after the Moderna COVID-19 vaccine (18 years of age or older). You may	
also receive a fifth (booster) dose 4 months after your fourth vaccine dose for	
the Pfizer-BioNTech COVID-19 vaccine (12 years of age or older) and 4 months	
after the Moderna COVID-19 vaccine (18 years of age or older). Your provider is	
best able to assess your degree of immunocompromise and optimal timing of	
vaccination. If you have received a single primary vaccine dose of the Janssen	
COVID-19 vaccine, then you may also receive an additional primary vaccine dose	
(Pfizer-BioNTech or Moderna preferred) 4 weeks after your initial Janssen	
vaccine dose.	
Moderate or severe immune compromise may be caused by:	
<ul> <li>Immunosuppressive therapies, such as active cancer treatment, CART-T-</li> </ul>	
cell therapy, high-dose steroids) or	
Medical conditions that affect the immune system, such as solid-organ	
transplant, stem cell transplant within last 2 years, moderate or severe	
primary immunodeficiency, advanced or untreated HIV infection.	
If you have completed a primary vaccine series with the Pfizer-BioNTech COVID-19 vaccine or the Moderna COVID-19 vaccine, do the below criteria apply to you?	☐ Yes ☐ No ☐ N/A
12 years of age or older for Pfizer-BioNTech COVID 19 vaccine	
18 years of age or older for Moderna COVID-19 vaccine	
The minimum amount of time has elapsed since your second dose	
<ul> <li>At least 5 months for the Pfizer-BioNTech COVID-19 vaccine</li> </ul>	
<ul> <li>At least 5 months for the Moderna COVID-19 vaccine</li> </ul>	
<ul> <li>50 years of age or older and at least 4 months has elapsed since your</li> </ul>	
first booster shot for the Pfizer-BioNTech or Moderna COVID-19	
vaccine	
Guidance: If yes, the Centers for Disease Control and Prevention (CDC)	
recommends a COVID-19 vaccine booster shot for you. While any of the	
currently available COVID-19 vaccines may be used for your booster dose, in	
most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred	
over the Janssen COVID-19 vaccine for booster vaccination.	Vac DAL DALA
If you have completed the single primary dose of the Janssen COVID-19 vaccine, do the below criteria apply to you?	☐ Yes ☐ No ☐ N/A
18 years of age or older	
At least 2 months has elapsed since your dose	

Question	Answer
Guidance: If yes, the CDC has indicated that you may receive a COVID-19 vaccine	
booster dose. While any of the currently available COVID-19 vaccines may be	
used for your booster dose, in most situations, Pfizer-BioNTech or Moderna	
COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for booster	
vaccination.	
Have you have received both a single primary dose and booster dose of the Janssen COVID-19 vaccine?	☐ Yes ☐ No ☐ N/A
Guidance: If yes, the CDC has indicated that you may receive a 2 <sup>nd</sup> booster	
dose using an mRNA COVID-19 vaccine (Pfizer BioNTech or Moderna COVID19	
vaccine) at least 4 months after your Janssen COVID-19 booster.	
Do you have underlying medical conditions, such as Guillain-Barré syndrome, Bell's	☐ Yes ☐ No
palsy, dermal filler use?	
Guidance: If yes, you may receive the COVID-19 vaccine (unless otherwise	
contraindicated). Clinical trials show similar results for people with these	
underlying medical conditions.	
Are you currently taking an anticoagulant (blood thinner)?	☐ Yes ☐ No
Guidance: If yes, you may see some bleeding at your injection site.	
Are you pregnant, planning on becoming pregnant, or breastfeeding?	☐ Yes ☐ No
Guidance: If yes, the Pfizer-BioNTech or Moderna COVID-19 vaccine is	
recommended for you.	
<ul> <li>There is no evidence that any of the COVID-19 vaccines affect current or</li> </ul>	
future fertility	
<ul> <li>COVID-19 vaccines do not cause infection in pregnant women or</li> </ul>	
their babies	
<ul> <li>No safety concerns in animal studies</li> </ul>	
<ul> <li>Reassuring early safety data on the Pfizer-BioNTech and</li> </ul>	
Moderna COVID-19 vaccines during pregnancy	
<ul> <li>Early data suggest the Pfizer-BioNTech and Moderna COVID-19</li> </ul>	
vaccines during pregnancy are effective	
Are you a woman younger than 50 years old?	☐ Yes ☐ No
<u>Guidance:</u> If yes, you should be aware of the rare risk of blood clots with low	
platelets after vaccination with the Janssen (J&J) COVID-19 vaccine. However,	
after temporarily pausing the use of this vaccine to review all available safety	
data, CDC and FDA recommend use of this vaccine start again, given that the	
known and potential benefits outweigh the known and potential risks. This	
adverse event is rare, occurring at a rate of about 7 per 1 million vaccinated	
women between 18 and 49 years old. For women 50 years and older and men of all ages, this adverse event is even more rare.	
For three weeks after receiving the vaccine, you should be on the lookout for	
possible symptoms of a blood clot with low platelets. These include:	
Severe or nonstop headaches or blurred vision	
Shortness of breath	
Chest pain	
Leg swelling	
Constant abdominal pain	
Easy bruising or tiny blood spots under the skin beyond the injection site	
Seek medical care right away if you develop one or more of these symptoms.	

#### References

- CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines. Published online March 1, 2021. Available from: <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/03-COVID-MacNeil.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/03-COVID-MacNeil.pdf</a>
- 2. Janssen. Fact sheet for healthcare providers administering vaccines. Emergency use authorization (EUA) of the Janssen COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). February 2021.
- 3. Moderna. Fact sheet for healthcare providers administering vaccines. Emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). December 2020.
- 4. Pfizer-BioNTech. Fact sheet for healthcare providers administering vaccines. Emergency use authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). December 2020.
- CDC. CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume. Published online 4/25/21. Available from: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html#symptoms-list-question">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html#symptoms-list-question</a>
- 6. CDC. Information about COVID-19 Vaccines for People who Are Pregnant or Breastfeeding. Published online 4/28/21. Available from: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html</a>
- 7. CDC. Clinical Considerations for Pfizer-BioNTech COVID-19 Vaccination in Adolescents. Published online 5/12/21. Available from: <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/05-COVID-Woodworth-508.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/05-COVID-Woodworth-508.pdf</a>
- 8. CDC. Clinical considerations for use of an additional mRNA COVID-19 vaccine dose after a primary mRNA COVID-19 vaccine series for immunocompromised people. Published online 8/13/21. Available from: <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-13/03-COVID-Goswami-508.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-13/03-COVID-Goswami-508.pdf</a>
- 9. CDC. Pfizer-BioNTech COVID-19 Vaccine Booster Shot. Published online 9/24/21. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
- 10. CDC. CDC Expands Eligibility for COVID-19 Booster Shots. Published online 10/21/21. Available from: <a href="https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html">https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html</a>
- 11. FDA. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. Published online 10/29/2021. Available from: <a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age">https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age</a>
- 12. CDC. CDC Expands Eligibility for COVID-19 Booster Shots to All Adults. Published online 11/19/2021. Available from: <a href="https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html">https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html</a>
- 13. CDC. CDC Expands COVID-19 Booster Recommendations to 16-and-17-year-olds. Published online 12/9/21. Avialable from: https://www.cdc.gov/media/releases/2021/s1208-16-17-booster.html
- 14. CDC. CDC Endorses ACIP's Updated COVID-19 Vaccine Recommendations. Published online 12/16/2021. Available from: https://www.cdc.gov/media/releases/2021/s1216-covid-19-vaccines.html
- 15. CDC. CDC Recommends Moderna Booster at 5 Months. Published online 1/7/22. Available from: <a href="https://www.cdc.gov/media/releases/2022/s0107-moderna-booster.html">https://www.cdc.gov/media/releases/2022/s0107-moderna-booster.html</a>
- 16. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines. Published online February 11, 2022. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
- 17. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines. Published online February 22, 2022. Available from: <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html</a>
- 18. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines. Published online March 30, 2021. Available from: <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html</a>